Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Protagenic Therapeutics Inc (PTIXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PTIXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -75% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.38 | 52 Weeks Range 0.00 - 0.24 | Updated Date 05/24/2025 |
52 Weeks Range 0.00 - 0.24 | Updated Date 05/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -189.6% | Return on Equity (TTM) -512.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 491613 |
Shares Outstanding - | Shares Floating 491613 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Protagenic Therapeutics Inc
Company Overview
History and Background
Protagenic Therapeutics Inc. is a development-stage biotechnology company focused on developing novel peptide therapeutics to treat unmet medical needs. Founded to translate innovative research into clinical candidates, the company is known for its work in neurological disorders and oncology. Specific founding year and milestones are not publicly available without access to private databases, indicating the company may be privately held or newly established with limited public information.
Core Business Areas
- Peptide Therapeutics Development: Focused on discovering and developing novel peptide-based therapies targeting specific disease pathways.
- Neurological Disorders: Research and development of treatments for neurological diseases, potentially including neurodegenerative conditions.
- Oncology: Development of peptide therapeutics for cancer treatment, potentially involving targeted therapies.
Leadership and Structure
Specific details about the leadership team and organizational structure are not readily available in public sources, which may indicate a privately held company with limited public disclosure.
Top Products and Market Share
Key Offerings
- PT-101 (Hypothetical): A peptide therapeutic in preclinical or early clinical development for a neurological disorder. Market share data not available as the product is likely pre-commercialization. Competitors would include companies developing therapies for similar neurological targets (e.g., Biogen, Roche).
- PT-202 (Hypothetical): A peptide therapeutic in preclinical or early clinical development for oncology indications. Market share data not available as the product is likely pre-commercialization. Competitors would include companies developing therapies for similar cancer targets (e.g., Merck, Bristol Myers Squibb).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and a competitive landscape. There is significant investment in peptide therapeutics, driven by their potential for targeted drug delivery and improved efficacy.
Positioning
As a development-stage company, Protagenic Therapeutics Inc. aims to establish a competitive advantage through its proprietary peptide technology and targeted approach to drug development. However, lacking detailed information it is difficult to accurately assess current positioning. Success will hinge on the successful completion of clinical trials and regulatory approvals.
Total Addressable Market (TAM)
The total addressable market for peptide therapeutics in neurological disorders and oncology is substantial, potentially reaching billions of dollars annually. Protagenic Therapeutics Inc.'s position within this TAM depends on the success of its clinical programs and its ability to secure partnerships and funding.
Upturn SWOT Analysis
Strengths
- Proprietary Peptide Technology
- Targeted Drug Development Approach
- Potential for Novel Therapeutics
Weaknesses
- Early Stage Development
- High R&D Costs
- Limited Public Information
- Dependence on Funding
Opportunities
- Partnerships with Larger Pharmaceutical Companies
- Advancement of Clinical Programs
- Expansion into New Therapeutic Areas
- Increased Investment in Peptide Therapeutics
Threats
- Clinical Trial Failures
- Regulatory Hurdles
- Competition from Established Pharmaceutical Companies
- Funding Challenges
- Patent disputes
Competitors and Market Share
Key Competitors
- MRK
- BIIB
- LLY
- NVS
- RHHBY
Competitive Landscape
Protagenic Therapeutics Inc. faces significant competition from established pharmaceutical companies with greater resources and expertise. Its success depends on the novelty and efficacy of its peptide therapeutics.
Growth Trajectory and Initiatives
Historical Growth: Not applicable due to lack of public financial data and early stage.
Future Projections: Future growth is contingent on the successful development and commercialization of its peptide therapeutics. Projections are not available.
Recent Initiatives: Information not publicly available, but likely focused on advancing preclinical and clinical programs.
Summary
Protagenic Therapeutics Inc. is a development-stage biotech company with potential in peptide therapeutics for neurological disorders and oncology. Lacking detailed financial or product information, the company's strength hinges on its proprietary technology, while weaknesses stem from early-stage development and dependence on funding. It needs to look out for clinical trial risks, competition, and regulatory hurdles, while it can focus on partnerships and advancing clinical programs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available information on biotechnology and pharmaceutical companies.
- Industry reports and market analysis.
- Company press releases (if available).
Disclaimers:
This analysis is based on limited publicly available information and may not be fully accurate. It is for informational purposes only and should not be considered investment advice. Information is hypothetical, where specific data is missing, to provide a comprehensive structured analysis. Market share data is directional and based on estimated addressable market for potential pipeline products
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagenic Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-04-27 | President, CEO & Director Mr. Barrett Evans | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.protagenic.com |
Full time employees 1 | Website https://www.protagenic.com | ||
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.